Overview

A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants

Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This first in human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and food effect of GBT021601, a hemoglobin S (HbS) polymerization inhibitor, in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Global Blood Therapeutics